ArticleJournal of medical physics2013
Superparamagnetic iron oxide-C595: Potential MR imaging contrast agents for ovarian cancer detection.
Article in Journal of medical physics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Iron oxide nanoparticles: a versatile nanoplatform for the treatment and diagnosis of ovarian cancer.Therapeutic delivery · 2025Review
- Medical imaging modalities using nanoprobes for cancer diagnosis: A literature review on recent findings.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2019Review
- Synthesis and Cytotoxicity Assessment of Gold-coated Magnetic Iron Oxide Nanoparticles.Journal of biomedical physics & engineering · 2018Article
- Identification of epidermal growth factor receptor-positive glioblastoma using lipid-encapsulated targeted superparamagnetic iron oxide nanoparticles in vitro.Journal of nanobiotechnology · 2017Article
- In vitro Study of SPIONs-C595 as Molecular Imaging Probe for Specific Breast Cancer (MCF-7) Cells DetectionIranian biomedical journal · 2017Article
- The role of biomarkers in the management of epithelial ovarian cancer.Expert review of molecular diagnostics · 2017Review
- Targeted Superparamagnetic Iron Oxide Nanoparticles for In Vivo Magnetic Resonance Imaging of T-Cells in Rheumatoid Arthritis.Molecular imaging and biology · 2017Article
- Ferroptosis is induced following siramesine and lapatinib treatment of breast cancer cells.Cell death & disease · 2016Article
- Selecting Targets for Tumor Imaging: An Overview of Cancer-Associated Membrane Proteins.Biomarkers in cancer · 2016Review
- Preparation of magnetic resonance probes using one-pot method for detection of hepatocellular carcinoma.World journal of gastroenterology · 2015Article
- Cobalt Zinc Ferrite Nanoparticles as a Potential Magnetic Resonance Imaging Agent: An In vitro Study.Avicenna journal of medical biotechnologyArticle
- Magnetic Iron Oxide Nanoparticles as TAvicenna journal of medical biotechnologyArticle
- Erratum: Superparamagnetic Iron Oxide-C595: Potential MR Imaging Contrast Agents for Ovarian Cancer Detection.Journal of medical physicsArticle
- Synthesis and Application of FeJournal of medical signals and sensorsArticle
- Aptamer-conjugated Magnetic Nanoparticles as Targeted Magnetic Resonance Imaging Contrast Agent for Breast Cancer.Journal of medical signals and sensorsArticle
Corrections and comments
- Erratum issued
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Superparamagnetic iron oxide nanoparticles (SPIONs), have played an important role in the promotion of image contrast in magnetic resonance imaging modality. The objective of present study is describing SPIONs conjugated with C595 monoclonal antibody (mAb) against MUC1-expressing ovarian cancer (OVCAR3) cell. Magnetic resonance imaging parameters of the prepared nanoconjugate was investigated in vitro: characterization, cell toxicity, flow cytometry, Prussian blue staining, and cellular uptake as well as biodistribution and magnetic resonance signal intensities under in vivo conditions were also investigated. Magnetic resonance imaging and biodistribution results showed good tumor accumulation and detection, no cytotoxicity, and potential selective as anti-ovarian cancer. In conclusion, based on the findings SPIONs-C595 nanosized-probe is potentially, a selective ovarian molecular imaging tool. Further subsequent in vivo studies and clinical trials are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.